TXN2

TXN2 is a mitochondria-targeted thioredoxin that functions as the central electron carrier in a three-component NADPH→thioredoxin reductase 2→TXN2→peroxiredoxin 3 (PRDX3) cascade that catalyzes NADPH-dependent reduction of mitochondrial hydrogen peroxide, thereby governing mitochondrial redox homeostasis, oxidative phosphorylation efficiency, and apoptotic signaling (PMID:9363753, PMID:18164269). By suppressing mitochondrial ROS, TXN2 restrains NF-κB-dependent inflammatory cytokine expression and BACE1 transcription, links AMPK-mediated glucose sensing to neuronal excitability in hypothalamic neurons, and protects skeletal muscle from age-related caspase-9/3-mediated atrophy (PMID:32920833, PMID:32839348, PMID:40236683, PMID:38246558). TXN2 expression is transcriptionally controlled by KAT2A-mediated H3K36 acetylation at its promoter and post-transcriptionally repressed by miR-27a/b, with TXN2 depletion causing G1 cell-cycle arrest (PMID:38417317, PMID:28356525). Complete human loss-of-function of TXN2 causes early-onset neurodegeneration with mitochondrial redox failure and OXPHOS dysfunction (PMID:26626369).

1. 1997 High

   The identification of TXN2 as a mitochondrial thioredoxin and reconstitution of the NADPH→TXN reductase→TXN2→SP-22(PRDX3) peroxide-reducing cascade established the core enzymatic function of TXN2 in mitochondrial H₂O₂ detoxification.

   Evidence Biochemical purification from bovine mitochondria with in vitro reconstitution of three-component NADPH-dependent peroxidase activity

   PMID:9363753

   Open questions at the time

   • Physiological importance of TXN2 in intact cells and organisms was not demonstrated
   • Whether TXN2 has substrates beyond PRDX3/SP-22 was unknown
   • Regulation of TXN2 expression was uncharacterized
2. 2007 High

   Haploinsufficiency studies in mice demonstrated that TXN2 is rate-limiting for mitochondrial ATP production, ETC complex activity, and suppression of ROS-induced apoptosis in vivo, establishing its non-redundant physiological role beyond peroxide clearance.

   Evidence Txn2+/− knockout mice with isolated mitochondrial ATP, ETC, ROS, oxidative damage, and TUNEL apoptosis assays in liver

   PMID:18164269

   Open questions at the time

   • Complete loss-of-function phenotype was unknown (homozygous KO is embryonic lethal)
   • Tissue-specific sensitivity to TXN2 reduction was not systematically explored
   • Molecular mechanism linking TXN2 loss to reduced ETC activity was not resolved
3. 2009 Medium

   Discovery that promoter insertion polymorphisms in human TXN2 reduce transcriptional activity and associate with neural tube defects connected TXN2 dosage to developmental pathology, consistent with mouse neural tube closure failure.

   Evidence Luciferase reporter assays in U2-OS and HEK293 cells; case-control association study for spina bifida

   PMID:19165900

   Open questions at the time

   • Population association does not establish causality for neural tube defects
   • Mechanism by which reduced TXN2 impairs neural tube closure was not defined
   • Other regulatory variants in TXN2 were not systematically surveyed
4. 2015 High

   Identification of a human patient with complete TXN2 loss-of-function demonstrated that TXN2 is essential for mitochondrial redox defense and OXPHOS in human cells, and its absence causes early-onset neurodegeneration — the first Mendelian disease linked to TXN2.

   Evidence Patient exome sequencing (homozygous stop mutation), immunoblot, ROS and OXPHOS assays in patient fibroblasts, lentiviral reconstitution rescue

   PMID:26626369

   Open questions at the time

   • Why neurons are selectively vulnerable to TXN2 loss was not explained
   • No structural or biochemical characterization of the mutant protein was performed
   • Whether partial loss-of-function alleles cause milder phenotypes is unknown
5. 2017 Medium

   Demonstration that miR-27a/b directly represses TXN2 via its 3′ UTR and that TXN2 knockdown causes G1 arrest revealed a post-transcriptional regulatory axis and an unexpected role for TXN2 in cell-cycle progression.

   Evidence miRNA mimic/inhibitor transfection, 3′ UTR luciferase reporter assay, siRNA knockdown, flow cytometry cell cycle analysis in human cell lines

   PMID:28356525

   Open questions at the time

   • Mechanism by which TXN2 depletion leads to G1 arrest was not defined (ROS-dependent or not)
   • Physiological contexts where miR-27 regulation of TXN2 is relevant beyond viral infection were not explored
   • Whether cell-cycle effects are conserved across cell types is unknown
6. 2020 High

   Multiple studies converged to show that TXN2 integrates into broader signaling networks: it suppresses NF-κB-driven inflammation and BACE1 transcription via ROS control, acts downstream of AMPK to sustain glucose-inhibited neuron activity in the hypothalamus, and interacts with PRDX3 in a tissue-context-dependent manner with functional redundancy in the cochlea.

   Evidence Bidirectional TXN2 manipulation with NF-κB epistasis in neuronal/adipocyte lines; conditional AMPK KO with Txn2 re-expression rescue in Sf1 neurons; Txn2+/− cochlear phenotyping

   PMID:32839348 PMID:32866605 PMID:32920833 PMID:38246558

   Open questions at the time

   • Direct physical interaction between AMPK and TXN2 promoter regulation was not demonstrated
   • Whether ROS-to-NF-κB signaling is the sole pathway through which TXN2 controls BACE1 is not resolved
   • Tissue-specific determinants of TXN2 redundancy (cochlea) versus essentiality (brain, liver) are unexplored
7. 2022 Medium

   TXN2 overexpression preserves aged skeletal muscle mass by suppressing mitochondrial ROS and caspase-9/3-mediated apoptosis, extending TXN2's anti-apoptotic role to a sarcopenia context, and Foxn1 was identified as a transcriptional activator of TXN2 in keratinocytes under hypoxia.

   Evidence TXN2 transgenic mice with muscle mass, transcriptomic, and apoptosis marker analysis; LC-MS/MS proteomics of Foxn1+/+ vs Foxn1−/− keratinocytes with in vivo confirmation

   PMID:35792861 PMID:40236683

   Open questions at the time

   • Whether TXN2 overexpression improves muscle function (contractile force) and not just mass is unknown
   • Whether Foxn1 binds the TXN2 promoter directly was not shown
   • Single-lab findings for both; independent replication is lacking
8. 2024 Medium

   Demonstration that KAT2A deposits H3K36ac at the TXN2 promoter to drive its transcription, with loss of KAT2A causing mitochondrial oxidative damage, defined a specific epigenetic mechanism controlling TXN2 expression.

   Evidence ChIP-qPCR for H3K36ac at the TXN2 promoter in SH-SY5Y cells; KAT2A overexpression rescue of TXN2 expression and mitochondrial damage

   PMID:38417317

   Open questions at the time

   • Whether KAT2A regulation of TXN2 operates in non-neuronal tissues is unknown
   • Contribution of other histone marks or chromatin remodelers to TXN2 transcription is unexplored
   • Single-lab study; independent validation is needed

• The structural basis for TXN2–PRDX3 interaction, the full spectrum of TXN2 substrates beyond PRDX3, and the molecular mechanism linking TXN2 loss to selective neuronal vulnerability remain unresolved.
• No crystal structure of human TXN2 or TXN2–PRDX3 complex has been reported
• Comprehensive substrate profiling of TXN2 (e.g., trapping mutant proteomics) has not been performed
• Mechanism of selective neurodegeneration upon TXN2 loss is unexplained